Mesolimbic dopamine reward system hypersensitivity in individuals with psychopathic traits

Nature Neuroscience

Volumn 13, Issue 4, 2010, Pages 419-421

  Buckholtz, Joshua W ^a,b   Treadway, Michael T ^a   Cowan, Ronald L ^a   Woodward, Neil D ^a   Benning, Stephen D ^a   Li, Rui ^a   Ansari, M Sib ^a   Baldwin, Ronald M ^a   Schwartzman, Ashley N ^a   Shelby, Evan S ^a   Smith, Clarence E ^a   Cole, David ^a   Kessler, Robert M ^a   Zald, David H ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DOPAMINE; FALLYPRIDE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANTISOCIAL BEHAVIOR; ARTICLE; BRAIN NERVE CELL; CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINE RELEASE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMPULSIVENESS; MESOLIMBIC DOPAMINERGIC SYSTEM; NEUROCHEMISTRY; NEUROPHYSIOLOGY; NUCLEUS ACCUMBENS; POSITRON; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOPATHY; REWARD; SINGLE BLIND PROCEDURE; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; ANTISOCIAL PERSONALITY DISORDER; BRAIN MAPPING; CRIMINALS; DOPAMINE; FEMALE; HUMANS; IMPULSIVE BEHAVIOR; LIMBIC SYSTEM; MAGNETIC RESONANCE IMAGING; MALE; NUCLEUS ACCUMBENS; PERSONALITY ASSESSMENT; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE; REWARD; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 77950187595     PISSN: 10976256     EISSN: None     Source Type: Journal    
DOI: 10.1038/nn.2510     Document Type: Article

References (15)

1. Anderson, D.A. J. Law Econ. 42, 611-642 (1999
2. Hare, R.D. Psychiatr. Clin. North Am. 29, 709-724 (2006).
3. Blair R.J. Phil. Trans. R. Soc. Lond. B Biol. Sci. 363 2557-2565 (2008).
4. Neumann, C.S. & Hare, R.D. J. Consult. Clin. Psychol. 76, 893-899 (2008).
5. Walters, G.D. Law Hum. Behav. 27, 541-558 (2003).
6. Skeem, J.L. & Mulvey, E.P. J. Consult. Clin. Psychol. 69, 358-374 (2001).
7. Edens, J.F., Poythress, N.G. Jr., Lilienfeld, S.O. & Patrick, C.J. Behav. Sci. Law 26, 529-541 (2008).
8. Smith, S.S. & Newman, J.P. J. Abnorm. Psychol. 99, 430-439 (1990).
9. Everitt, B.J. et al. Phil. Trans. R. Soc. Lond. B 363, 3125-3135 (2008).
10. Benning, S.D., Patrick, C.J., Hicks, B.M., Blonigen, D.M. & Krueger, R.F. Psychol. Assess. 15, 340-350 (2003).
11. Lewis, M.H., Gariepy, J.L., Gendreau, P. , Nichols, D.E. & Mailman, R.B. Neuropsychopharmacology 10, 115-122 (1994).
12. Schott, B.H. et al. J. Neurosci. 28, 14311-14319 (2008).
13. Ferrari, P.F., van Erp, A.M., Tornatzky, W. & Miczek, K.A. Eur. J. Neurosci. 17, 371-378 (2003).
14. Couppis, M.H. & Kennedy, C.H. Psychopharmacology (Berl.) 197, 449-456 (2008).
15. Rodriguiz, R.M., Chu, R., Caron, M.G. & Wetsel, W.C. Behav. Brain Res. 148, 185-198 (2004).